
Bristol-Myers Squibb has unveiled new Phase 2 data for its investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, known as …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

